Novo Nordisk Alters Gender Representation Strategy in U.S.
Novo Nordisk has decided to drop gender representation targets for senior roles in its U.S. business. This follows executive orders from President Trump halting diversity initiatives. The change aligns Novo with other European firms like Roche and Novartis reacting to similar regulations.
Novo Nordisk, a leading obesity drugmaker, announced on Wednesday a significant policy shift regarding gender representation in the United States. The company decided to abandon its global gender representation targets for U.S. senior leadership roles, influenced by recent executive orders from President Donald Trump aimed at stopping diversity, equity, and inclusion policies.
Despite sustaining a firm commitment internationally to a minimum of 45% gender representation by 2025, Novo Nordisk's U.S. operations will not partake in this global aspirational goal due to shifting legal landscapes. This move mirrors actions taken by other European pharmaceutical giants like Roche and Novartis.
Since Trump's inauguration, Novo had upheld its dedication to a diverse workforce. However, adjusting their U.S. strategy, they align with peers avoiding penalties from recent executive actions, a trend also seen with Swiss company Roche and GSK's similar announcements earlier this year.
(With inputs from agencies.)
Google News